PharmaCyte Biotech (PMCB) Net Income towards Common Stockholders (2010 - 2026)
PharmaCyte Biotech's Net Income towards Common Stockholders was -$5.79 million in fiscal Q1 2027 (quarter ended Jul 31, 2026), compared with -$8.36 million a year earlier.
Powered by 
Analysis
PharmaCyte Biotech (PMCB) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, PharmaCyte Biotech's Net Income towards Common Stockholders was -$20.63 million through Jul 31, 2026; for FY2026 (ended Apr 30, 2026), it was -$23.21 million.
- In earlier fiscal years, Net Income towards Common Stockholders was $23.36 million in FY2025, -$17.24 million in FY2024, -$4.32 million in FY2023 and -$4.24 million in FY2022.
- Quarterly Net Income towards Common Stockholders has moved between -$8.42 million (fiscal Q2 2026) and $20.59 million (fiscal Q1 2025) over five years.
- Per Business Quant data, PMCB's Net Income towards Common Stockholders in the three fiscal quarters before Q1 2027 was -$4.87 million (Q4 2026), -$1.56 million (Q3 2026) and -$8.42 million (Q2 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | PharmaCyte Biotech | 4.29 Mn | 4.29 Mn | - | -5.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | -5.79 Mn |
| Apr 30, 2026 | -4.87 Mn |
| Jan 31, 2026 | -1.56 Mn |
| Oct 31, 2025 | -8.42 Mn |
| Jul 31, 2025 | -8.36 Mn |
| Apr 30, 2025 | 8.78 Mn |
| Jan 31, 2025 | -3.05 Mn |
| Oct 31, 2024 | -2.96 Mn |
| Jul 31, 2024 | 20.59 Mn |
| Apr 30, 2024 | -2.54 Mn |
| Jan 31, 2024 | -5.62 Mn |
| Oct 31, 2023 | -2.26 Mn |
| Jul 31, 2023 | -6.78 Mn |
| Apr 30, 2023 | -126,338.00 |
| Jan 31, 2023 | -764,136.00 |
| Oct 31, 2022 | -1.88 Mn |
| Jul 31, 2022 | -1.55 Mn |
| Apr 30, 2022 | -1.42 Mn |
| Jan 31, 2022 | -811,290.00 |
| Oct 31, 2021 | -979,746.00 |
API Access
PharmaCyte Biotech Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=PMCB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "PMCB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=PMCB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();